BIOGEN INC (BIIB)
NASDAQ • Healthcare
Last close at August 10, 2026 at 20:00 UTC
Fundamentals Charts
About BIOGEN INC
Biogen Inc. develops, manufactures, and markets therapies for neurological, neurodegenerative, autoimmune, and blood-related diseases. Listed on NASDAQ as BIIB, the company sits within the healthcare sector as a branded drug maker, and it recorded $9.8 billion in revenue in FY2025.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
BIOGEN INC's Technical Indicators Summary
Biogen’s technical picture supports the strong-buy stance as short- and medium-term moving averages sit above the 200-day average and price is trading well above major long-term support, while momentum measures such as MACD and a positive momentum reading favor buyers. Trend strength remains modest, with ADX indicating a lack of a powerful directional trend, and volatility is contained given a mid-range ATR. On-balance volume is weaker, suggesting some distribution amid otherwise constructive price structure. Technical takeaway: bias favors buyers on a broadly bullish moving-average and momentum setup, though trend strength is muted.
| Indicator | Value |
|---|---|
RSI (14) | 53.25 |
Stochastic %K (14, 3, 3) | 47.05 |
CCI (20) | 80.11 |
WPR (14) | -52.88 |
Momentum (10) | 6.99 |
MFI | 64.07 |
MACD Level (12, 26) | 1.40 |
Bollinger Bands | $194.30 - $212.89 |
ATR (14) | $7.13 (3.44%) |
ADX (14) | 17.91 |
OBV | 42,136,605 |
Classic Pivot Point | $206.80 |
Fibonacci Pivot Point | $206.80 |
Simple Moving Averages | $185.20 - $206.40(5 indicators) |
Exponential Moving Averages | $182.90 - $205.94(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
BIIB recorded a minor loss during the previous session, ticking down to 207.13.
Trading Volume
Below 10d avg (1.2M)
687.4K
vs S&P 500 Today
Moderate Underperformance
-0.33%
52-Week Position
Upper range
86.2%
Updated: August 11, 2026 at 12:31 UTC
Quote Summary
BIIB Headlines
Biogen’s diranersen shows mid-stage Alzheimer’s gains
July 14, 2026
Big Pharma Updates: Trials, Deals and Ratings
April 27, 2026
Analysts Reassess Tech Names Ahead of Earnings
February 27, 2026
ETFs and Asian Stocks Stand Out in Volatile Markets
February 8, 2026